$%^STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections

```
 NEWS 29  JUN 25  CA/CAplus and USPAT databases updated with IPC
                  reclassification data
 NEWS 30  JUN 30  AEROSPACE enhanced with more than 1 million U.S.
                  patent records
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:02:52 ON 21 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:03:33 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 JUL 2008  HIGHEST RN 1035004-20-6
DICTIONARY FILE UPDATES:  20 JUL 2008  HIGHEST RN 1035004-20-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
```

on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10550381.str

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR
/ Structure 1 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 15:04:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   5 TO ITERATE

100.0% PROCESSED   5 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 5 TO   234
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:04:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   86 TO ITERATE

100.0% PROCESSED   86 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

L3   1 SEA SSS FUL L1

=> d scan

L3   1 ANSWERS   REGISTRY COPYRIGHT 2008 ACS on STN
IN   Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-
     quinoxalinyl)methyl]amino]methyl]-
MF   C10 H11 N4 O7 P

/ Structure 2 in file .gra /

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 178.82 | 179.03

FILE 'CAPLUS' ENTERED AT 15:04:49 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008 (20080720/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 12 L3

=> d ibib abs hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:529982 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 148:487209
TITLE: Combination therapy using an allosteric adenosine A1 receptor enhancer with an opioid analgesic or AMPA/kainate antagonists for the treatment of pain
INVENTOR(S): Eisenach, James Conrad
PATENT ASSIGNEE(S): King Pharmaceuticals Research and Development, Inc., USA
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2008051760	A2	20080502	WO 2007-US81598	20071017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080108603	A1	20080508	US 2007-872800	20071016
US 20080108622	A1	20080508	US 2007-872859	20071016
US 20080113969	A1	20080515	US 2007-872878	20071016
PRIORITY APPLN. INFO.:			US 2006-852815P	P 20061019
			US 2007-872800	A 20071016
			US 2007-872859	A 20071016
			US 2007-872878	A 20071016

AB The invention provides synergistic combinations for the treatment of conditions assocd. with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain assocd. with migraine. In particular, the invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric adenosine A1 receptor enhancer combination with opioid analgesic or AMPA/kainate antagonist for treatment of pain)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 3 in file .gra /

=> d 1-12 ibib abs hitstr

L4 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2008:529982 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER:	148:487209
TITLE:	Combination therapy using an allosteric adenosine A1 receptor enhancer with an opioid analgesic or AMPA/kainate antagonists for the treatment of pain
INVENTOR(S):	Eisenach, James Conrad
PATENT ASSIGNEE(S):	King Pharmaceuticals Research and Development, Inc., USA
SOURCE:	PCT Int. Appl., 54pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008051760	A2	20080502	WO 2007-US81598	20071017
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080108603	A1	20080508	US 2007-872800	20071016
US 20080108622	A1	20080508	US 2007-872859	20071016
US 20080113969	A1	20080515	US 2007-872878	20071016

PRIORITY APPLN. INFO.:	US 2006-852815P	P	20061019
	US 2007-872800	A	20071016
	US 2007-872859	A	20071016
	US 2007-872878	A	20071016

AB The invention provides synergistic combinations for the treatment of conditions assocd. with pain including acute pain, e.g., postoperative pain, chronic pain, inflammatory pain, neuropathic pain and pain assocd. with migraine. In particular, the invention relates to the use of an allosteric adenosine A1 receptor enhancer in conjunction with opioid analgesics or 2-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)/kainate antagonists for alleviating pain, e.g., postoperative pain.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric adenosine A1 receptor enhancer combination with opioid analgesic or AMPA/kainate antagonist for treatment of pain)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 4 in file .gra /

L4 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2007:908914 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER:	147:355935
TITLE:	Epilepsy
AUTHOR(S):	Knutsen, L. J. S.; Williams, M.
CORPORATE SOURCE:	Worldwide Discovery Research, Cephalon Inc., West Chester, PA, USA
SOURCE:	Comprehensive Medicinal Chemistry II (2006), Volume 6, 279-296. Editor(s): Taylor, John B.; Triggle, David J. Elsevier Ltd.: Oxford, UK. CODEN: 69JQHZ; ISBN: 978-0-08-044513-7
DOCUMENT TYPE:	Conference; General Review

LANGUAGE: English

AB A review on recent developments in diagnosis and treatment of epilepsy. The disease state and disease basis are discussed, along with exptl. disease models, clin. trial issues, current treatments, and unmet medical needs. Emerging research areas are also addressed, including adenosine producing stem cell therapy, novel GABA transporter inhibitors, and .omega. fatty acids.

IT ***188696-80-2*** , Becampanel
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(becampanel has been used for treatment of seizures in patient with epilepsy)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 5 in file .gra /

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1111722 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 146:74520

TITLE: A microplate solid scintillation counter as a radioactivity detector for high performance liquid chromatography in drug metabolism: Validation and applications

AUTHOR(S): Bruin, Gerard J.; Waldmeier, Felix; Boernsen, K. Olaf; Pfaar, Ulrike; Gross, Gerhard; Zollinger, Markus

CORPORATE SOURCE: Drug Metabolism & Pharmacokinetics, Novartis Pharma AG, Basel, CH-4002, Switz.

SOURCE: Journal of Chromatography, A (2006), 1133(1-2), 184-194
CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sensitive radioactivity detection following high performance liq. chromatog. (HPLC) sepn. remains a challenge in many drug metab. studies with radiolabeled compds. In this work, solid scintillation counting (SSC) after fraction collection into 96-well plates was evaluated as an off-line radioactivity detection method, in comparison with conventional liq. scintillation counting (LSC). The impact of counting time and biol. matrix on the quantification of radiolabeled metabolites and parent drug in samples from animal and human absorption, distribution, metab. and excretion (ADME) studies was investigated. Three different approaches were used to test whether reliable quantification by off-line SSC detection, which requires an approx. const. counting yield during the entire chromatog. run, can be realized: (i) the measurement of radioactivity-spiked biol. blank samples without HPLC sepn. as an extreme case of biol. background, (ii) the measurement of radioactivity-spiked HPLC fractions of biol. blank samples and (iii) the comparison of radio chromatograms obtained by off-line SSC and LSC of real samples from ADME studies with radiolabeled compds. Situations in which variations in SSC yield during an HPLC run are likely to lead to significant errors in

quantitation were identified and are discussed. However, examples from a no. of animal or human ADME studies showed that in the majority of cases off-line SSC provides very similar quant. data, compared with the ref. method of off-line LSC radioactivity detection. Approaches for validation of the off-line SSC approach in crit. cases are discussed. The main advantages of off-line SSC, compared with off-line LSC, are lower detection limits and a substantially higher throughput. Several applications of off-line SSC detection in ADME studies are shown.

IT ***188696-80-2*** , Amp397
RL: ANT (Analyte); ANST (Analytical study)
(microplate solid scintillation counter combined with HPLC for high throughput drug metab. screening)

RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 6 in file .gra /

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:395110 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 142:435803
TITLE: Combinations comprising AMPA receptor antagonists for the treatment of neuropathic pain
INVENTOR(S): Karolchyk, Mary Ann; Lingenhoehl, Kurt; Ofner, Silvio; Fox, Alyson
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039593	A1	20050506	WO 2004-EP11870	20041020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-24542 A 20031021
OTHER SOURCE(S): MARPAT 142:435803

AB The present invention relates to combinations suitable for the treatment of pain, esp. neuropathic pain. The combinations comprise at least 1 AMPA receptor antagonist and at least one combination partner selected from the group consisting of cyclooxygenase inhibitors, vanilloid receptor

antagonists, opioids, tricyclic antidepressants, anticonvulsants, cathepsin S inhibitors and GABAB receptor agonists. {[(7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl)amino]methyl}phosphonic acid may be administered to a patient in a total daily dosage of 60-400 mg.

IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations comprising AMPA receptor antagonists for the treatment of neuropathic pain)

RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 7 in file .gra /

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:995976 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 141:406122
TITLE: Use of substituted aminoalkanephosphonic acids in the treatment of multiple sclerosis and related demyelinating diseases
INVENTOR(S): Foster, Carolyn Ann; Hiestand, Peter C.; Lingenhoehl, Kurt
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 11 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098603	A1	20041118	WO 2004-EP5043	20040511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-10868 A 20030512
OTHER SOURCE(S): MARPAT 141:406122

AB The present invention relates to a new pharmaceutical use of substituted aminoalkanephosphonic acids, esp. multiple sclerosis and related demyelinating diseases.

IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(aminoalkanephosphonic acids for treatment of multiple sclerosis and related demyelinating diseases)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 8 in file .gra /

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857406 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 141:325767
TITLE: Combinations of antiepileptic drugs for the treatment of neurological disorders
INVENTOR(S): Aitken, David; Lingenhohl, Kurt; Schmutz, Markus
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087161	A1	20041014	WO 2004-EP3518	20040402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226825	A1	20041014	AU 2004-226825	20040402
AU 2004226825	B2	20070816		
CA 2521274	A1	20041014	CA 2004-2521274	20040402
EP 1620103	A1	20060201	EP 2004-725366	20040402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009170	A	20060411	BR 2004-9170	20040402
CN 1767832	A	20060503	CN 2004-80009218	20040402
JP 2006522062	T	20060928	JP 2006-504970	20040402
US 20060194766	A1	20060831	US 2005-550381	20050921
IN 2005CN02527	A	20070831	IN 2005-CN2527	20051004
PRIORITY APPLN. INFO.:			GB 2003-7860 A	20030404
			WO 2004-EP3518 W	20040402

OTHER SOURCE(S): MARPAT 141:325767
AB The invention discloses combinations comprising two antiepileptics, pharmaceutical compns. comprising such combinations, and the use of such combinations for the prepn. of a medicament for the treatment of neurol.

disorders, esp. epilepsy.
IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiepileptic drug combination for treatment of neurol. disorder)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 9 in file .gra /

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:892622 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 139:358798
TITLE: New uses of substituted aminoalkanephosphonic acids
INVENTOR(S): Lingenhoehl, Kurt; Auberson, Yves; Fox, Alyson; Neijt, Hans C.; Kalkman, Hans O.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092701	A2	20031113	WO 2003-EP4466	20030429
WO 2003092701	A3	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2482524	A1	20031113	CA 2003-2482524	20030429
AU 2003232224	A1	20031117	AU 2003-232224	20030429
EP 1501518	A2	20050202	EP 2003-747434	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009611	A	20050209	BR 2003-9611	20030429
CN 1649599	A	20050803	CN 2003-809597	20030429
JP 2005527600	T	20050915	JP 2004-500885	20030429
ZA 2004007642	A	20060628	ZA 2004-7642	20040922
MX 2004PA10816	A	20050307	MX 2004-PA10816	20041029
US 20060293282	A1	20061228	US 2004-512923	20041029
NO 2004005089	A	20041123	NO 2004-5089	20041123
PRIORITY APPLN. INFO.:			GB 2002-9886 A	20020430
			GB 2002-9887 A	20020430
			GB 2002-9889 A	20020430
			GB 2002-10371 A	20020507

GB 2002-12760 A 20020531
WO 2003-EP4466 W 20030429
WO 2003-US4466 W 20030429

OTHER SOURCE(S): MARPAT 139:358798

AB The present invention relates the use of substituted aminoalkanephosphonic acids in treating neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders.

IT ***188696-80-2***
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted aminoalkanephosphonic acids for treatment of mental disorders and nervous system disorders)

RN 188696-80-2 CAPLUS

CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 10 in file .gra /

L4 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:512328 CAPLUS <<LOGINID::20080721>>

DOCUMENT NUMBER: 138:147543

TITLE: Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound

AUTHOR(S): Suter, Willi; Hartmann, Andreas; Poetter, Franziska; Sagelsdorff, Peter; Hoffmann, Peter; Martus, Hans-Jorg

CORPORATE SOURCE: Toxicology/Pathology, Novartis Pharma AG, Basel, 4002, Switz.

SOURCE: Mutation Research, Genetic Toxicology and Environmental Mutagenesis (2002), 518(2), 181-194
CODEN: MRGMFI; ISSN: 1383-5718

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB AMP397 is a novel antiepileptic agent and the first competitive AMPA antagonist with high receptor affinity, good in vivo potency, and oral activity. AMP397 has a structural alert (arom. nitro group) and was mutagenic in Salmonella typhimurium strains TA97a, TA98 and TA100 without S9, but neg. in the nitroreductase-deficient strains TA98NR and TA100NR. The amino deriv. of AMP397 was neg. in wild-type strains TA98 and TA100. AMP397 was neg. in a mouse lymphoma tk assay, which included a 24 h treatment without S9. A weak micronucleus induction in vitro was found at the highest concns. tested in V79 cells with S9. AMP397 was neg. in the following in vivo studies, which included the max. tolerated doses of 320 mg/kg in mice and 2000 mg/kg in rats: Muta Mouse assay in colon and liver (5.times.320 mg/kg) at three sampling times (3, 7 and 31 days after the last administration); DNA binding study in the liver of mice and rats after a single treatment with [14C]-AMP397; comet assay (1.times.2000 mg/kg) in jejunum and liver of rats, sampling times 3 and 24 h after administration; micronucleus test (2.times.320 mg/kg) in the bone marrow of mice, sampling 24 h after the second administration. Based on these results, it was concluded that AMP397 has no genotoxic potential in vivo. In particular, no genotoxic metabolite is formed in mammalian cells, and, if formed by intestinal bacteria, is unable to exert any genotoxic activity in the adjacent intestinal tissue. These data were considered to provide sufficient safety to initiate clin. development of the compd.

IT ***188696-80-2*** , AMP 397
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (genotoxicity assessment of antiepileptic drug AMP397, an Ames-pos. arom. nitro compd.)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 11 in file .gra /

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:222645 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 137:257504
TITLE: N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: In vivo active AMPA and NMDA (glycine) antagonists
AUTHOR(S): Auberson, Yves P.; Acklin, Pierre; Bischoff, Serge; Moretti, Robert; Ofner, Silvio; Schmutz, Markus; Veenstra, Siem J.
CORPORATE SOURCE: Novartis Pharma AG, Basel, 4002, Switz.
SOURCE: Biomedical and Health Research (2001), 45(Excitatory Amino Acids: Ten Years Later), 37-42
CODEN: BIHREN; ISSN: 0929-6743
PUBLISHER: IOS Press
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:257504
AB N-Substituted 5-aminomethylquinoxalinediones contg. carboxy or phosphonic acids yield potent and selective AMPA and/or NMDA (glycine-binding site) antagonists. Phosphonic acid derivs. are particularly water-sol. and display potent anticonvulsant effects in the electroshock-induced convulsion assay in mice.
IT ***188696-80-2P***
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones and activity as in vivo active AMPA and NMDA (glycine) antagonists and anticonvulsants)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 12 in file .gra /

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:118530 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 130:306031
TITLE: N-Phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists

AUTHOR(S): Auberson, Yves P.; Acklin, Pierre; Bischoff, Serge; Moretti, Robert; Ofner, Silvio; Schmutz, Markus; Veenstra, Siem J.
CORPORATE SOURCE: Novartis Pharma AG, Basel, 4002, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(2), 249-254
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-Substituted 5-aminomethylquinoxalinediones contg. carboxy or phosphonic acids yield potent and selective AMPA and/or NMDA (glycine-binding site) antagonists. Phosphonic acid derivs. are particularly water-sol. and display potent anticonvulsant effects in the electroshock-induced convulsion assay in mice.

IT ***188696-80-2P***
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phosphonoalkyl aminomethylquinoxalinediones as in vivo active AMPA and NMDA(glycine) antagonists, and prepn., receptor binding, and anticonvulsant activity)
RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 13 in file .gra /

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:268508 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 128:321753
ORIGINAL REFERENCE NO.: 128:63785a,63788a
TITLE: Substituted aminoalkane phosphonic acids
INVENTOR(S): Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Ofner, Silvio; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Ofner, Silvio; Veenstra, Siem Jacob
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817672	A1	19980430	WO 1997-EP5843	19971022

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2269807	A1	19980430	CA 1997-2269807		19971022
CA 2269807	C	20070410			
AU 9851885	A	19980515	AU 1998-51885		19971022
EP 934326	A1	19990811	EP 1997-946755		19971022
EP 934326	B1	20060503			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO					
CN 1234037	A	19991103	CN 1997-199101		19971022
CN 1092202	B	20021009			
BR 9713489	A	20000229	BR 1997-13489		19971022
JP 2001502681	T	20010227	JP 1998-518970		19971022
JP 3908790	B2	20070425			
HU 2000000383	A2	20010528	HU 2000-383		19971022
HU 2000000383	A3	20030128			
RU 2181362	C2	20020420	RU 1999-110376		19971022
IL 129394	A	20020523	IL 1997-129394		19971022
SK 282548	B6	20021008	SK 1999-523		19971022
AT 325128	T	20060615	AT 1997-946755		19971022
PT 934326	T	20060831	PT 1997-946755		19971022
PL 192286	B1	20060929	PL 1997-332775		19971022
ES 2264171	T3	20061216	ES 1997-946755		19971022
NO 9901902	A	19990621	NO 1999-1902		19990421
KR 2000052747	A	20000825	KR 1999-703547		19990423
US 6117873	A	20000912	US 1999-297010		19990423
PRIORITY APPLN. INFO.:			CH 1996-2621	A	19961024
			WO 1997-EP5843	W	19971022

OTHER SOURCE(S): MARPAT 128:321753
GI

/ Structure 14 in file .gra /

AB The prepn. of title compds. I (R1 = OH, aliph., araliph. or arom. radical; X = bivalent aliph., cycloaliph., cycloaliph.-aliph., araliph., heteroarylaliph. or arom. radical; R2 = H or an aliph. or araliph. radical; alk = lower alkylidene; R3, R4, R5 = independently represent H, lower alkyl, halogen, trifluoromethyl, cyano or nitro) is described. I and their salts may be used for treating pathol. conditions which respond to the blocking of exciter amino acid receptors, and for producing pharmaceutical compns.

IT ***188696-80-2P***
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted aminoalkane phosphonic acids as amino acid receptors)

RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 15 in file .gra /

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:278950 CAPLUS <<LOGINID::20080721>>
DOCUMENT NUMBER: 126:251169
ORIGINAL REFERENCE NO.: 126:48567a,48570a
TITLE: Preparation of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands
INVENTOR(S): Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Acklin, Pierre; Allgeier, Hans; Auberson, Yves; Biollaz, Michel; Moretti, Robert; Ofner, Silvio; Veenstra, Siem Jacob
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708155	A1	19970306	WO 1996-EP3644	19960819
W: AL, AU, BB, BG, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2227851	A1	19970306	CA 1996-2227851	19960819
AU 9668742	A	19970319	AU 1996-68742	19960819
AU 705871	B2	19990603		
EP 853617	A1	19980722	EP 1996-929275	19960819
EP 853617	B1	20040303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
CN 1193968	A	19980923	CN 1996-196581	19960819
HU 9801676	A2	19990329	HU 1998-1676	19960819
HU 9801676	A3	19990428		
JP 11511444	T	19991005	JP 1997-509801	19960819
JP 3159711	B2	20010423		
IL 122987	A	20010808	IL 1996-122987	19960819
AT 260902	T	20040315	AT 1996-929275	19960819
PT 853617	T	20040630	PT 1996-929275	19960819
ES 2217324	T3	20041101	ES 1996-929275	19960819
PL 189637	B1	20050930	PL 1996-324992	19960819
TW 438782	B	20010607	TW 1996-85110230	19960822
IN 1996MA01489	A	20071026	IN 1996-MA1489	19960823
ZA 9607322	A	19970228	ZA 1996-7322	19960829
NO 9800814	A	19980421	NO 1998-814	19980226
NO 310236	B1	20010611		
US 6080743	A	20000627	US 1998-29525	19980227
HK 1010196	A1	20050121	HK 1998-111287	19981016
PRIORITY APPLN. INFO.:			CH 1995-2479 A	19950831
			CH 1995-2734 A	19950927

	CH 1995-2747	A	19950928
	CH 1996-1213	A	19960510
	CH 1996-1630	A	19960628
	CH 1996-1214	A	19960510
	WO 1996-EP3644	W	19960819

OTHER SOURCE(S): MARPAT 126:251169
GI

/ Structure 16 in file .gra /

AB The title compds. [I; one of R1 and R2 = R5 and the other = CH(R6)-alk-R7, alk-CH(R6)R7, etc. (wherein R5 = R3, R4; R6 = unsubstituted or lower alkylated and/or lower alkanoylated amino; R7 = H, an aliph., cycloaliph., heterocycloaliph. radical, etc.); R3, R4 = H, lower alkyl, halo, etc.], useful in the prepn. of a medicament for the treatment of pathol. conditions that are responsive to blocking of AMPA, kainate and/or glycine binding sites of the NMDA receptor, were prepd. and formulated. Thus, reaction of 7-bromo-5-bromomethyl-2,3-dimethoxyquinoxaline with glycine tert-Bu ester hydrochloride in the presence of Et3N in MeCN followed by deesterification afforded the title compd. II.HBr. Compds. I are effective at 10-500 mg/day when administered orally to 75 kg patient.

IT ***188696-80-2P***
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivs. as AMPA, kainate and/or glycine binding sites of the NMDA receptor ligands)

RN 188696-80-2 CAPLUS
CN Phosphonic acid, P-[[[(1,2,3,4-tetrahydro-7-nitro-2,3-dioxo-5-quinoxalinyl)methyl]amino]methyl]- (CA INDEX NAME)

/ Structure 17 in file .gra /

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	71.33	250.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.40	-10.40

STN INTERNATIONAL LOGOFF AT 15:05:35 ON 21 JUL 2008